- Tirzepatide (Mounjaro, Zepbound) is a once-weekly injection whose side effects are mostly digestive and mostly mild, but a few warnings are serious and worth knowing.
- The most common effects are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain.
- Serious warnings on the label include acute pancreatitis, gallbladder problems, kidney injury from dehydration, low blood sugar (especially with other diabetes drugs), and severe allergic reactions.
- The label carries a boxed warning about thyroid C-cell tumors seen in rodents; it is contraindicated for people with a personal or family history of medullary thyroid cancer or MEN 2.
- Severe, persistent abdominal pain, signs of an allergic reaction, or symptoms of very low blood sugar are reasons to seek care promptly.
- Because dosing and monitoring are individualized, take tirzepatide exactly as prescribed and report bothersome or worrying symptoms to your clinician.
PASTE BELOW THIS LINE INTO THE WORDPRESS EDITOR
— (everything below is the HTML body) —
Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea — is a once-weekly injection that has become widely used. If you have been prescribed it or are considering it, you likely want a straightforward overview of the tirzepatide side effects: which ones are common and usually manageable, which are serious, and how to tell them apart. This article is built around that practical question — not just a list, but a sense of what to expect and, importantly, when a symptom is a reason to call your doctor. It is general education, not medical advice, and it does not replace the guidance of the clinician who prescribed the drug.
How tirzepatide works, briefly
Understanding the side effects is easier with a little context. Tirzepatide acts on gut hormone pathways (it is described as a GIP and GLP-1 receptor agonist). Among other effects, MedlinePlus notes it helps the pancreas release insulin when blood sugar is high and slows how quickly the stomach empties, which reduces appetite. That slowing of the digestive system is exactly why most of the common side effects are stomach-related. It is injected under the skin once a week, and prescribers typically start low and increase the dose gradually, in part to help the body adjust and ease those digestive effects.
The common side effects
The most frequently reported effects are digestive, and for many people they are mild to moderate and tend to ease as the body adjusts, especially after the early weeks or a dose increase. According to MedlinePlus and the drug’s labeling, the common ones include:
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Indigestion (dyspepsia)
- Abdominal (stomach) pain
Injection-site reactions and fatigue are also reported. These effects are common enough that they are worth planning for rather than being surprised by. Simple measures often help — smaller meals, eating more slowly, staying hydrated — but if they are severe or persistent, tell your clinician, who may adjust the pace of dose changes. For a closer look at these early effects, see the common early side effects in more detail.
The serious warnings to know
Most people will not experience the serious effects, but they are the ones worth recognizing. The label and MedlinePlus flag several:
- Acute pancreatitis — inflammation of the pancreas. The hallmark is severe, persistent stomach pain that may radiate to the back, sometimes with vomiting.
- Gallbladder problems — including gallstones, which can cause upper-right abdominal pain, fever, or yellowing of the skin or eyes.
- Kidney injury — usually linked to dehydration from heavy vomiting or diarrhea, which is one reason staying hydrated matters.
- Low blood sugar (hypoglycemia) — more likely when tirzepatide is combined with other diabetes medicines such as insulin or sulfonylureas. Symptoms include shakiness, sweating, confusion, and dizziness.
- Serious allergic reactions — such as rash, hives, swelling, or trouble breathing.
- Vision changes in people with diabetic eye disease, which should be monitored.
The thyroid boxed warning
Tirzepatide’s label carries a boxed warning about thyroid C-cell tumors, including medullary thyroid carcinoma. This is based on studies in rats; the label states that the human relevance of that finding has not been determined. Because of it, tirzepatide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or the genetic syndrome MEN 2. The label advises reporting symptoms such as a neck lump, trouble swallowing, shortness of breath, or persistent hoarseness. This warning is precautionary rather than proof of human cancer, but it is a genuine reason the drug is not appropriate for certain people — which is why family history is part of the prescribing conversation.
| Category | Examples | General response |
|---|---|---|
| Common, often mild | Nausea, diarrhea, low appetite, constipation, indigestion | Self-care measures; mention if severe or persistent |
| Serious, seek care | Severe abdominal pain, gallbladder symptoms, signs of dehydration | Contact a clinician promptly |
| Urgent / emergency | Trouble breathing or swelling (allergy); severe low blood sugar | Seek emergency care |
When to call your doctor
A useful rule of thumb: mild, easing digestive symptoms are usually something to manage and monitor, while certain symptoms warrant a call or a visit. Contact your clinician promptly for severe or lasting abdominal pain (especially pain that spreads to the back), signs of dehydration you cannot keep up with, or gallbladder symptoms like upper-right belly pain, fever, or yellowing skin. Seek emergency care for signs of a serious allergic reaction — swelling of the face, lips, or throat, or trouble breathing — or for severe low blood sugar. And report the thyroid symptoms above. For a suspected overdose or accidental extra dose, call Poison Control at 1-800-222-1222, or 911 for an emergency.
Using tirzepatide as prescribed
Dosing and monitoring for tirzepatide are individualized — set and adjusted by your prescriber based on your condition, response, and other medicines. Take it exactly as prescribed, do not change the dose or schedule on your own, and keep your clinician informed about side effects, both to stay safe and because some can be eased by adjusting the approach. If you are weighing whether the benefits are worth the risks over months and years, our companion piece on what’s known about long-term side effects goes further into that question.
Frequently asked questions
What are the most common tirzepatide side effects? Digestive ones — nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain — which are often mild and tend to ease with time.
Do the side effects go away? For many people the common digestive effects lessen as the body adjusts, particularly after the early weeks or after a dose increase settles.
What are the most serious risks? Acute pancreatitis, gallbladder problems, kidney injury from dehydration, low blood sugar (especially with other diabetes drugs), serious allergic reactions, and the thyroid boxed warning.
Can tirzepatide cause low blood sugar? On its own the risk is lower, but it rises when combined with insulin or sulfonylureas. Watch for shakiness, sweating, and confusion.
Who should not take tirzepatide? People with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, per the label. Others should discuss their history with a prescriber.
When should I call my doctor? For severe or persistent abdominal pain, signs of an allergic reaction, symptoms of very low blood sugar, or the thyroid warning signs — and seek emergency care for breathing trouble or facial swelling.
This article is general education and is not medical advice. Talk to a qualified clinician about your situation.
For more on medications and when symptoms warrant care, see our medical conditions guide.
Sources
- MedlinePlus (U.S. National Library of Medicine) — Tirzepatide Injection drug information
- DailyMed (U.S. National Library of Medicine) — Tirzepatide (Mounjaro) prescribing information, including the Boxed Warning
- U.S. Food and Drug Administration (FDA) — Tirzepatide approval and labeling
- American Association of Poison Control Centers — Poison Help line, 1-800-222-1222